Warning: The NCBI web site requires JavaScript to function. more...
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J.
Breast Cancer Res. 2006;8(2):R13. Epub 2006 Mar 15. Erratum in: Breast Cancer Res. 2006;8(3):406.
Related citations
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L.
J Clin Oncol. 2002 Aug 1;20(15):3219-24.
Bisphosphonates for breast cancer.
Pavlakis N, Schmidt R, Stockler M.
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review.
Pavlakis N, Stockler M.
Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.
Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.
Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J.
Drug Saf. 2003;26(9):661-71.
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E.
Bull Cancer. 2001 Jul;88(7):701-7. French.
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, Dearnaley DP; Medical Research Council PR04 Collaborators.
J Natl Cancer Inst. 2007 May 16;99(10):765-76.
Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Powles T, McCroskey E, Paterson A.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6301s-6304s. Review.
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
Saarto T, Blomqvist C, Virkkunen P, Elomaa I.
J Clin Oncol. 2001 Jan 1;19(1):10-7.
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK; Mrc Pr05 Collaborators.
J Natl Cancer Inst. 2003 Sep 3;95(17):1300-11.
Meta-analysis of clodronate and breast cancer survival.
Ha TC, Li H.
Br J Cancer. 2007 Jun 18;96(12):1796-801. Epub 2007 Feb 27.
Bisphosphonates and breast carcinoma.
Lipton A.
Cancer. 1997 Oct 15;80(8 Suppl):1668-73. Review.
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S.
J Clin Oncol. 1993 Jan;11(1):59-65.
Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J.
J Natl Cancer Inst. 1998 May 6;90(9):704-8.
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F.
Ann Oncol. 2008 Dec;19(12):2007-11. Epub 2008 Jul 29.
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.
N Engl J Med. 1998 Aug 6;339(6):357-63.
Clodronate: a review of its use in breast cancer.
Hurst M, Noble S.
Drugs Aging. 1999 Aug;15(2):143-67. Review.
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
Saarto T, Vehmanen L, Virkkunen P, Blomqvist C.
Acta Oncol. 2004;43(7):650-6.
Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
McCloskey E, Paterson A, Kanis J, Tähtelä R, Powles T.
Eur J Cancer. 2010 Feb;46(3):558-65. Epub 2009 Dec 22.
Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I.
Breast Cancer Res Treat. 2005 Mar;90(2):117-25.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on